HYBRID EVENT: You can participate in person at Tokyo, Japan from your home or work.
Atypical Teratoid Rhabdoid Tumor (ATRT) is a rare and aggressive form of cancer that primarily affects the central nervous system, especially the brain and spinal cord. This tumor is most commonly found in young children, with a peak incidence in children under the age of 3. ATRT is characterized by its rapid growth and propensity to spread to other parts of the central nervous system.
The term "atypical teratoid" reflects the unusual and diverse cell types present in the tumor. Additionally, the presence of rhabdoid cells, which are large and irregular cells, distinguishes ATRT from other central nervous system tumors.
Symptoms of ATRT may vary depending on the location and size of the tumor but often include signs of increased intracranial pressure such as headaches, vomiting, and changes in behavior. Due to its aggressive nature, ATRT requires prompt and comprehensive medical intervention.
The diagnosis of ATRT involves a combination of imaging studies, such as magnetic resonance imaging (MRI) or computed tomography (CT) scans, and a biopsy to examine the tumor tissue. Treatment typically involves a multi-modal approach, including surgery, radiation therapy, and chemotherapy.
Despite aggressive treatment, the prognosis for ATRT can be challenging, and the outcomes vary. Research into new treatment modalities and a better understanding of the underlying genetic factors driving ATRT are ongoing to improve therapeutic strategies and outcomes for individuals affected by this rare and aggressive tumor. As ATRT is a complex and evolving area of study, collaboration among healthcare professionals, researchers, and support networks is crucial in advancing our knowledge and enhancing the care of those impacted by this condition.
